Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
45results about How to "Few adverse effect" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
InactiveUS20120094894A1Reduce weightAvoiding weight increaseAntibacterial agentsBiocideIGT - Impaired glucose toleranceAcute hyperglycaemia
The invention relates to antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia, inter alia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions. The medication is a mono treatment with a DPP-4 inhibitor <preferably linagliptin> or a combination treatment with a DPP-4 inhibitor and a second and / or third antidiabetic.
Owner:BOEHRINGER INGELHEIM INT GMBH
Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
ActiveUS20130196898A1Weight increaseLose weightBiocidePeptide/protein ingredientsPatient groupGenotype
Owner:BOEHRINGER INGELHEIM INT GMBH
Tranexamic acid formulations
InactiveUS20050244495A1Minimize and eliminate undesirable gastrointestinal side effectReduce concentrationBiocidePill deliveryTranexamic acidPharmacology
Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.
Owner:AMRING PHARM INC +1
Pharmaceutical composition, methods for treating and uses thereof
InactiveUS20130035281A1Good effectFew adverse effectAntibacterial agentsSenses disorderIGT - Impaired glucose toleranceAcute hyperglycaemia
The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and a GLP-1 receptor agonist which is suitable in the treatment or prevention of diabetes mellitus, impaired glucose tolerance, hyperglycemia or other conditions. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
Owner:BOEHRINGER INGELHEIM INT GMBH
Tranexamic Acid Formulations
ActiveUS20100143468A1Minimize and eliminate undesirable gastrointestinal side effectReduce concentrationBiocideNervous disorderTranexamic acidPharmacology
Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.
Owner:AMRING PHARM INC
Tranexamic acid formulations
InactiveUS20090215898A1Less side effectsFew adverse effectBiocideOrganic active ingredientsImmediate releaseTranexamic acid
Disclosed are immediate release oral tranexamic acid formulations and methods of treatment therewith.
Owner:AMRING PHARM INC
Tranexamic acid formulations
ActiveUS20090209646A1Minimize and eliminate undesirable gastrointestinal side effectReduce concentrationBiocidePeptide/protein ingredientsTranexamic acidPharmacology
Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.
Owner:AMRING PHARM INC
Modified peptides and proteins
InactiveUS20140309168A1High binding affinityStrong specificityPeptide/protein ingredientsAntibody mimetics/scaffoldsSolubilityDisease
Owner:AMIDE BIO
Pharmaceutical composition, methods for treating and uses thereof
InactiveUS20120283169A1Preventing and slowing progression of and delaying and treating diabetesGood effectOrganic active ingredientsSenses disorderAcute hyperglycaemiaIGT - Impaired glucose tolerance
The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions
Owner:BOEHRINGER INGELHEIM INT GMBH
Tranexamic acid formulations
Owner:XANODYNE PHARMACEUTICALS INC +1
Modified peptides and proteins
InactiveUS20130137645A1Enhance solubility and pharmacokinetic propertyHigh binding affinityPeptide-nucleic acidsPeptide/protein ingredientsPeptideProtein protein
Provided are compounds and methods of making compounds containing two or three groups derived from a peptide, such as enfuvirtide or exenatide, covalently bound to a linker. The compounds may contain polyethylene glycol groups to enhance solubility and pharmacokinetic properties. The compounds are useful for the treatment of diseases or conditions subject to treatment with the parent peptide, such as HIV and AIDS in the case of enfuvirtide, or diabetes in the case of exenatide.
Owner:AMIDE BIO
High molecular weight derivative of nucleic acid antimetabolite
ActiveUS20100029849A1Good effectFew adverse effectOrganic active ingredientsSugar derivativesSide chainPolyethylene glycol
[Problems] A derivative of a nucleic acid antimetabolite is demanded which can show a higher therapeutic effect at a lower dose.[Means for Solving Problems] Disclosed is a high molecular weight derivative a nucleic acid antimetabolite, which is characterized by comprising a high molecular weight compound comprising a polyethylene glycol moiety and a polymer moiety having a carboxyl group in a side chain and a nucleoside derivative which can act as a nucleic acid antimetabolite, wherein the nucleoside derivative is bound to the carboxyl group in the side chain of the high molecular weight compound via a highly hydrophobic linker.
Owner:NIPPON KAYAKU CO LTD
Pharmaceutical composition, methods for treating and uses thereof
InactiveUS20140087996A1Good effectFew adverse effectAntibacterial agentsSenses disorderIGT - Impaired glucose toleranceAcute hyperglycaemia
Owner:BOEHRINGER INGELHEIM INT GMBH
Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
ActiveUS9457029B2Good effectFew adverse effectPeptide/protein ingredientsMetabolism disorderPatient groupDiabetic patient
Owner:BOEHRINGER INGELHEIM INT GMBH
High molecular weight derivative of nucleic acid antimetabolite
ActiveUS8188222B2Good effectGood treatment effectOrganic active ingredientsSugar derivativesSide chainPolyethylene glycol
Owner:NIPPON KAYAKU CO LTD
Tranexamic acid formulations
InactiveUS20080280981A1Few adverse effectBiocidePeptide/protein ingredientsTranexamic acidPharmacology
Owner:AMRING PHARM INC
Tranexamic acid formulations
ActiveUS20090048341A1Minimize and eliminate undesirable gastrointestinal side effectReduce concentrationBiocidePeptide/protein ingredientsTranexamic acidPharmacology
Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.
Owner:AMRING PHARM INC
Pharmaceutical composition, methods for treating and uses thereof
InactiveUS20140256624A1Good effectFew adverse effectOrganic active ingredientsSenses disorderAcute hyperglycaemiaIGT - Impaired glucose tolerance
The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions
Owner:BOEHRINGER INGELHEIM INT GMBH
Tranexamic acid formulations
ActiveUS8273795B2Minimize and eliminate undesirable gastrointestinal side effectReduce concentrationBiocidePeptide/protein ingredientsPharmacologyTranhexamic acid
Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.
Owner:AMRING PHARM INC
Tranexamic acid formulations
ActiveUS7947739B2Minimize and eliminate undesirable gastrointestinal side effectReduce concentrationBiocideNervous disorderTranexamic acidPharmacology
Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.
Owner:AMRING PHARM INC
Tranexamic acid formulations
ActiveUS8022106B2Minimize and eliminate undesirable gastrointestinal side effectReduce concentrationBiocidePeptide/protein ingredientsMedicineTranexamic acid
Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.
Owner:AMRING PHARM INC
1,2,4-triazine-6-carboxamide derivative
ActiveUS20140343038A1Excellent syk inhibitory activityFew adverse effectBiocideOrganic chemistryNitrogen atomPerylene derivatives
The present invention provides a compound represented by the following general formula (I) or a salt thereof which has a Syk inhibitory effect (in the formula R1 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; A represents a hydrogen atom, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C2-C6 alkynyl group, an optionally substituted C3-C10 cycloalkyl group, an optionally substituted C6-C14 aromatic hydrocarbon group, an optionally substituted 4- to 10-membered unsaturated heterocyclic group, or an optionally substituted 4- to 10-membered saturated heterocyclic group, or optionally forms a 4- to 10-membered unsaturated heterocyclic ring or a 4- to 10-membered saturated heterocyclic ring together with R1 and the nitrogen atom bonded thereto; R2 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; and B represents an optionally substituted unsaturated heterocyclic group).
Owner:TAIHO PHARMA CO LTD
Ink composition, ink set, ink cartridge using the ink composition, inkjet recording method and recorded material
InactiveUS20080220168A1Reduce adhesionBeautiful materialMeasurement apparatus componentsDuplicating/marking methodsGlycol ethersDiacetylene
An ink composition having, as essential components, at least a diacetylene tetraol compound represented by general formula (1) below and a glycol ether represented by general formula (2) below:(wherein R1 and R2 each independently represent C1-3 alkyl groups, —O-Et- represents oxyethylene, and k, l, m and n are each integers from 0 to 2);(wherein R represents a C8 alkyl group, and n is an integer from 4 to 8).
Owner:SEIKO EPSON CORP
Tranexamic Acid Formulations
ActiveUS20110230559A1Few adverse effectBiocideOrganic active ingredientsImmediate releaseTranexamic acid
Owner:AMRING PHARM INC
Modified peptides and proteins
InactiveUS20150374840A1High binding affinityStrong specificityBiocidePeptide/protein ingredientsDiseaseSolubility
Owner:AMIDE BIO
Agent for prevention and/or treatment of systemic lupus erythematosus
InactiveUS20100120732A1Few adverse effectEliminate the effects ofBiocideOrganic chemistryLupus erythematosusAdverse effect
Provided is an agent for prevention and / or treatment of systemic lupus erythematosus, which comprises, in combination, 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazine-3-one or a solvate thereof and a corticosteroid. The pharmaceutical agent of the present invention is orally administrable, has fewer adverse effects, exhibits an excellent effect of suppressing the symptoms associated with SLE, and thus is useful for prevention and treatment of SLE.
Owner:KOWA CO LTD
Ink composition, ink set, ink cartridge using the ink composition, inkjet recording method and recorded material
InactiveUS7540911B2Reduce adhesionBeautiful materialMeasurement apparatus componentsDuplicating/marking methodsDiacetyleneGlycol ethers
Owner:SEIKO EPSON CORP
Antidiabetic medications
InactiveUS20150105318A1Good effectFew adverse effectAntibacterial agentsBiocideIGT - Impaired glucose toleranceAcute hyperglycaemia
Methods of using antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, and hyperglycemia, among others.
Owner:BOEHRINGER INGELHEIM INT GMBH
Compositions comprising sulfated polysaccharides
ActiveUS20200171075A1Good anti-inflammatory effectLess severe side effectSalicyclic acid active ingredientsSenses disorderDiseaseSulfated polysaccharides
The present invention provides a synergistic anti-inflammatory composition comprising one more anti-inflammatory agents such as a steroid, non-steroidal anti-inflammatory drug (NSAID) or a cannabinoid in combination with one or more sulfated polysaccharides. The invention is further directed to a method of treating inflammation and inflammatory diseases using said synergistic composition.
Owner:SEANERGY DERMATOLOGY LTD
1,2,4-triazine-6-carboxamide derivative
ActiveUS9145414B2Excellent Syk inhibitory activityGood choiceOrganic chemistryAntineoplastic agentsHydrogen atomTriazine
The present invention provides a compound represented by the following general formula (I) or a salt thereof which has a Syk inhibitory effect (in the formula R1 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; A represents a hydrogen atom, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C2-C6 alkynyl group, an optionally substituted C3-C10 cycloalkyl group, an optionally substituted C6-C14 aromatic hydrocarbon group, an optionally substituted 4- to 10-membered unsaturated heterocyclic group, or an optionally substituted 4- to 10-membered saturated heterocyclic group, or optionally forms a 4- to 10-membered unsaturated heterocyclic ring or a 4- to 10-membered saturated heterocyclic ring together with R1 and the nitrogen atom bonded thereto; R2 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; and B represents an optionally substituted unsaturated heterocyclic group).
Owner:TAIHO PHARMA CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com